CA4551001 – KAT6
03 Jan 2023
Trial Summary
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with either fulvestrant or letrozole + palbociclib.
Acronym:
KAT6
ACTRN/NCT /ethics:
NCT04606446
Scientific title:
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
Sponsor / Cooperative group:
Pfizer
Trial & Patient Characteristics
| Cancer Type | Solid tumours |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced, Metastatic or Widespread |
| Anticipated Start Date | 2020-11-16 |
| Anticipated End Date | 2027-09-23 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Rohit Joshi |
| Recruitment Status | Recruiting |